Immuneering (IMRX) Gains from Investment Securities (2020 - 2024)
Historic Gains from Investment Securities for Immuneering (IMRX) over the last 5 years, with Q4 2024 value amounting to -$5469.0.
- Immuneering's Gains from Investment Securities fell 12267.92% to -$5469.0 in Q4 2024 from the same period last year, while for Dec 2024 it was -$6784.0, marking a year-over-year decrease of 7222.65%. This contributed to the annual value of -$6784.0 for FY2024, which is 7222.65% down from last year.
- According to the latest figures from Q4 2024, Immuneering's Gains from Investment Securities is -$5469.0, which was down 12267.92% from -$1315.0 recorded in Q3 2024.
- In the past 5 years, Immuneering's Gains from Investment Securities registered a high of $3.8 million during Q2 2022, and its lowest value of -$5469.0 during Q4 2024.
- In the last 5 years, Immuneering's Gains from Investment Securities had a median value of $311183.0 in 2020 and averaged $1.3 million.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 83383.04% in 2021, then plummeted by 12267.92% in 2024.
- Quarter analysis of 5 years shows Immuneering's Gains from Investment Securities stood at $1.8 million in 2020, then skyrocketed by 58.75% to $2.9 million in 2021, then tumbled by 100.18% to -$5170.0 in 2022, then surged by 52.5% to -$2456.0 in 2023, then tumbled by 122.68% to -$5469.0 in 2024.
- Its Gains from Investment Securities stands at -$5469.0 for Q4 2024, versus -$1315.0 for Q3 2024 and -$2456.0 for Q4 2023.